Optimal sequencing in the treatment of recurrent ovarian cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Gynecologic Oncology

• Publication date

  2003-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0090-8258(03)00471-2PMID 13129495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug resistance in ovarian cancer — the role of p53

  2008cited by this paper
• Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2)

  2003cited by this paper
• Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.

  2003cited by this paper
• Clinical experience with topotecan in relapsed ovarian cancer.

  2003cited by this paper
• Weekly topotecan in the management of ovarian cancer.

  2003cited by this paper
• Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

  2002cited by this paper
• Cancer Statistics, 2002

  2002cited by this paper
• Relapsed ovarian cancer: challenges and management strategies for a chronic disease.

  2002cited by this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cited by this paper
• Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

  2000cited by this paper
• Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

  2000cited by this paper
• Phase II study of gemcitabine in ovarian cancer.

  1999cited by this paper
• Cancer multidrug resistance

  1999cited by this paper
• Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

  1998cited by this paper
• A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

  1998cited by this paper
• Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

  1998cited by this paper
• Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity.

  1998cited by this paper
• Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.

  1998cited by this paper
• Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

  1997cited by this paper
• Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

  1996cited by this paper
• Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

  1996cited by this paper
• Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

  1996cited by this paper
• Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.

  1995cited by this paper
• Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.

  1994cited by this paper
• Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.

  1992cited by this paper
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

  1991cited by this paper
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

  1990cited by this paper
• Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

  1989cited by this paper

• gBRCA1 and gBRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study.

  2025cites this paper
• Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes

  2022cites this paper
• Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?

  2019influential citation
• The Response of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

  2019cites this paper
• Réintroduction d’un traitement médicamenteux (chimiothérapie ou inhibiteur de récepteur à tyrosine kinase) dans les cancers bronchiques non à petites cellules : étude rétrospective monocentrique

  2017influential citation
• Cancer de l’ovaire : la rechute précoce

  2017cites this paper
• Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).

  2016cites this paper
• The optimal time for surgery in women with serous ovarian cancer.

  2016cites this paper
• Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

  2015cites this paper
• Immunomodulatory therapy in refractory/recurrent ovarian cancer.

  2015cites this paper
• Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

  2013cites this paper
• Screening and Identification of Biomarkers in Ascites Related to Intrinsic Chemoresistance of Serous Epithelial Ovarian Cancers

  2012cites this paper
• Long-term topotecan therapy in recurrent or persistent ovarian cancer.

  2011cites this paper
• Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer

  2011cites this paper
• Targeted therapy in ovarian cancer : novel agents and predictive biomarkers

  2011cites this paper
• "Targeted Therapy in ovarian cancer: novel agents and predictive biomarkers"

  2011cites this paper
• Aktuelles Management beim Ovarialkarzinomrezidiv

  2011cites this paper
• Kopf-Hals-Tumoren

  2011cites this paper
• Targeted treatment of recurrent platinum-resistant ovarian cancer : current and emerging therapies

  2010cites this paper
• Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

  2010cites this paper
• Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial.

  2010cites this paper
• Imaging in recurrent ovarian cancer

  2010cites this paper
• Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC)

  2009cites this paper
• Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.

  2009cites this paper
• Cox-2 immunohistochemical expression in epithelial ovarian carcinoma and platin sensitivity.

  2009cites this paper
• Treatment for Recurrent Ovarian Cancer—At First Relapse

  2009cites this paper
• The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.

  2009cites this paper
• Oral etoposide for refractory or recurrent epithelial ovarian cancer.

  2009cites this paper
• CA-125 AUC as a predictor for epithelial ovarian cancer relapse

  2008cites this paper
• Phase II multicenter open‐label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study

  2008cites this paper
• Atlas of staging in gynecological cancer

  2007cites this paper
• Serum soluble Fas levels and prediction of response to platinum‐based chemotherapy in epithelial ovarian cancer

  2007cites this paper
• A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

  2007cites this paper
• Update in the management of ovarian and cervical carcinoma

  2007cites this paper
• Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study

  2007cites this paper
• Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma

  2006cites this paper
• Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.

  2006cites this paper
• Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers

  2005cites this paper
• Treatment options in the management of ovarian cancer

  2005cites this paper
• Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.

  2005cites this paper
• Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review

  2004cites this paper
• Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma

  2004cites this paper
• Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.

  2004cites this paper
• The Response Rate of Carboplatin/Paclitaxel for the Platinum Sensitive Recurrent Ovarian Cancer Patients

  2003cites this paper
• Workshop: options for therapy in ovarian cancer.

  2003cites this paper
• Weekly topotecan in the management of ovarian cancer.

  2003cites this paper
• Clinical experience with topotecan in relapsed ovarian cancer.

  2003cites this paper
• Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.

  1992cites this paper